Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Cocks, Grahama | Wilde, Jonathan I.c | Graham, Simon Jc | Bousgouni, Vickyc | Virley, Davidd | Lovestone, Simona; b | Richardson, Jilld; *
Affiliations: [a] Department of Neuroscience, MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Denmark Hill, London, UK | [b] Department of Psychological Medicine, King's College London, Institute of Psychiatry, Denmark Hill, London, UK | [c] Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, New Frontiers Science Park, Harlow Essex, CM19 5AW, UK | [d] Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow Essex, CM19 5AW, UK
Correspondence: [*] Corresponding author: Jill Richardson, Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow Essex, CM19 5AW, United Kingdom. E-mail: [email protected].
Abstract: In a recent clinical study, the thiazolidinedione (TZD) pioglitazone (Actos™ was reported to preserve cognitive function in patients with mild to moderate Alzheimer's disease and type II diabetes mellitus. TZDs are agonists of the nuclear hormone receptor peroxisome proliferator-activated receptor-γ (PPARγ), are peripheral insulin sensitizers, and have recently been reported to increase mitochondrial biogenesis in the central nervous system and dendritic spine density. We report a transcriptional profile of the TZD pioglitazone and the non-TZD PPARγ agonist GW347845 in primary cortical culture. We observed that pioglitazone, but not GW347845, increased cholesterol biosynthetic and lipogenic gene expression after 6 h, and the expression of the cholesterol efflux transporters Abca1 and Abcg1 after 24 h. Co-treatment of pioglitazone with the PPARγ antagonist GW9662 did not significantly reduce these effects, suggesting a PPARγ-independent mechanism. These findings suggest a novel effect of TZDs in neurons that may be of relevance as a novel approach against Alzheimer's disease.
Keywords: ABCA1, Alzheimer's disease, cholesterol biosynthesis, thiazolidinediones
DOI: 10.3233/JAD-2010-1266
Journal: Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 631-646, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]